Methionine induces an increase of brain levels of 1) SAM (Table 2); 2) reelin and GAD67
promoter methylation (Fig. 2 and Dong et al., 2007, 2008), and 3) downregulation of reelin
and GAD67 mRNA (Fig. 3) and cognate protein expression (Tremolizzo et al., 2002, 2005).
GAD67 and reelin are not the only gene promoters hypermethylated by methionine
treatment. ChIP-on-chip assays show that in mice receiving methionine, about 5% of the
genome promoters are hypermethylated in the FC (Dong et al., 2008). Interestingly, the
GAD65, NSE (Fig. 3), and glyceraldehyde-3-phosphate dehydrogenase (G3PDH) promoters
are not hypermethylated by the administration of methionine, suggesting that promoter
hypermethylation is cell- and gene-specific.
As shown in Fig. 1, if methionine is withdrawn after seven days of treatment, reelin
promoter hypermethylation decreases by ~50% after the seventh day and returns to control
levels after 12–14 days of methionine withdrawal.
Methyl donors have been identified as important epigenetic factors contributing to the
aberrant regulation of reelin and other gene promoters. For example, maternal methionine
supplementation in rats induces epigenetic variations including DNA methylation alterations
in offspring (Weaver et al., 2006). Further, there is an epigenomic reprogramming of reelin
and glucocorticoid receptors in hippocampal pyramidal neurons after methionine
administration (Weaver et al., 2006). Our studies in cultured cortical neurons (Kundakovic
et al., 2009, Noh et al., 2005) not only show that the hypermethylation of promoters induced
by methionine is blocked by siRNA-mediated DNMT-KO or by DNMT antagonists but also
that this blockade induces the overexpression of reelin, GAD67, or BDNF (Kundakovic et
al., 2009).
Collectively, these data challenge the classic concept that DNA 5-mC patterns remain stable
in postmitotic cells and strongly suggest that by increasing SAM brain content, methionine
facilitates the promoter methylation mediated by DNMT1 or DNMT3a in the CNS. Unlike
the DNA sequence of a cell, which is stable and strongly conserved, epigenetic processes are
highly dynamic: they can be tissue-specific, developmentally-regulated, and modified by
exposure to a range of drugs or environmental factors (Ptak and Petronis, 2008, Szyf, 2005).NIH-PA Author ManuscriptNIH-PA Author Manuscript
NIH-PA Author ManuscriptfunctionValproate (VPA) and other histone deacetylase (HDAC) inhibitors promotechromatin remodeling, induce DNA-demethylation, and regulate cognitive
The dynamic nature of the epigenome means that, unlike pathogenic DNA sequence
mutations, epigenetic disruptions are potentially reversible and thus a realistic target for
pharmacological intervention.
In psychiatry, the use of VPA as a drug that enhances GABAergic transmission is based on
the observation that protracted VPA treatment in rodents induces an increase of GAD67
expression (Fig. 3) (see also Loscher et al., 1999, Tremolizzo et al. 2002). Recent studies
from our group and others suggest that GAD67 and reelin are increased by VPA because this
drug not only inhibits HDACs and modifies the “histone code” but also decreases
DNA methylation and demethylation神经疾病靶点_生物学_自然科学_专业资料。Pharmacological...Epigenetic GABAergic targets in schizophrenia and bipolar disorder. Neuroph...
et al.Disease-associated epigenetic changes in monozygotic twins discordant for schizophrenia and bipolar disorder. Hum Mol Genet. 2011; 20: 4786-4796. Rogd...
et al.Disease-associated epigenetic changes in monozygotic twins discordant for schizophrenia and bipolar disorder. Hum Mol Genet. 2011; 20: 4786-4796. Rogd...
热门文档